2.86

1.72% -0.05

After Hours: 2.86

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $2.86, with a volume of 2.77M. It is down -1.72% in the last 24 hours and up +6.72% over the past month. Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.

Previous Close:

$2.91

Open:

$2.91

24h Volume:

2.77M

Relative Volume:

1.09

Market Cap:

$318.38M

Revenue:

Net Income/Loss:

$-167.86M

P/E Ratio:

-1.247

EPS:

-2.2935

Net Cash Flow:

$-132.31M

1W Performance:

-8.63%

1M Performance:

+6.72%

6M Performance:

+4.38%

1Y Performance:

+118.32%

1-Day Range:

$2.78

$2.94

1-Week Range:

$2.78

$3.25

52-Week Range:

$1.11

$3.78

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1108)

Industry

Biotechnology (620)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

156

Twitter

@CabalettaBio

Next Earnings Date

2026-05-21

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA Cabaletta Bio Inc	2.86	323.95M	0	-167.86M	-132.31M	-2.2935
VRTX Vertex Pharmaceuticals Inc	430.14	108.36B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	731.77	78.05B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	775.03	48.74B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	302.11	41.16B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	298.16	33.17B	5.36B	287.73M	924.18M	2.5229

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-10-25	Resumed	Jefferies	Buy
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-10-24	Initiated	UBS	Buy
Feb-05-24	Initiated	Jefferies	Buy
Nov-29-23	Initiated	William Blair	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	Stifel	Buy
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

02:09 AM

Cellares, Cabaletta Bio Ink 10-Year Commercial Supply Pact for Investigational CAR-T Therapy - Contract Pharma

02:09 AM

12:46 PM

Cellares and Cabaletta Bio Sign 10-Year Commercial Supply Agreement to Scale Rese-cel - BioSpace

12:46 PM

10:26 AM

Cabaletta Bio signs 10-year manufacturing deal with Cellares By Investing.com - Investing.com Canada

08:28 AM

08:23 AM

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-cel - The Manila Times

08:23 AM

08:17 AM

Cellares, Cabaletta Bio sign 10-year manufacturing deal for rese-cel - Investing.com Canada

08:17 AM

08:00 AM

10-year rese-cel supply deal aims for thousands of patients a year - Stock Titan

08:00 AM

07:31 AM

Cabaletta Bio (NASDAQ: CABA) targets 600M authorized shares and equity plan changes - Stock Titan

07:31 AM

Apr 27, 2026

Cabaletta Bio shares climb after insider purchases - MSN

Apr 27, 2026

Cabaletta Bio, Inc. to Present New Data on Rese-cel at ASGCT 2026 Annual Meeting - Quiver Quantitative

Apr 27, 2026

Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting - The Manila Times

Apr 27, 2026

New autoimmune cell therapy data lead Cabaletta's Boston meeting talks - Stock Titan

Apr 27, 2026

Apr 24, 2026

OneIM Acquisition Corp. (OIM) - Minichart

Apr 24, 2026

Apr 23, 2026

Cabaletta (CABA) Moat Analysis | Cabaletta Bio Inc. beats EPS estimates by 15.6%High Interest Stocks - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Cabaletta Bio slides on proposed securities offering - MSN

Apr 23, 2026

Apr 21, 2026

William Blair Maintains Cabaletta Bio(CABA.US) With Buy Rating - Moomoo

Apr 21, 2026

Apr 20, 2026

Cabaletta Bio’s Rese-cel: Transforming Autoimmune Disease Treatment with CD19-CAR T Cell Therapy, No Preconditioning, and Automated Manufacturing 1 - Minichart

Apr 20, 2026

Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans - TipRanks

Apr 20, 2026

Cabaletta Bio posts April 2026 corporate presentation highlighting rese-cel trial progress, no-preconditioning data and automated manufacturing plans - TradingView

Apr 20, 2026

Rese-cel data expands across autoimmune diseases at Cabaletta Bio (CABA) - Stock Titan

Apr 20, 2026

Apr 19, 2026

Cabaletta reports results, advances Rese-Cel autoimmune program - MSN

Apr 19, 2026

Apr 18, 2026

Wall Street Zen Downgrades Cabaletta Bio (NASDAQ:CABA) to Sell - MarketBeat

Apr 18, 2026

Apr 17, 2026

Cabaletta Bio (Nasdaq: CABA) asks shareholders to double authorized common stock - Stock Titan

Apr 17, 2026

CABA News | CABALETTA BIO INC (NASDAQ:CABA) - ChartMill

Apr 17, 2026

Apr 15, 2026

Cellares’ Cell Shuttle used in first patient infusions of Cabaletta Bio CAR T therapy (CABA:NASDAQ) - Seeking Alpha

Apr 15, 2026

CABA: Cabaletta Bio Advances CAR T Cell Therapy with Cellares' Technology - GuruFocus

Apr 15, 2026

Apr 14, 2026

First Patients Dosed with Cabaletta Bio’s Rese-cel Manufactured on Cellares' Automated Cell Shuttle™ Platform - 01net

Apr 14, 2026

Cabaletta Bio Doses First Patients With Rese-cel Manufactured on Cellares' Automated Platform - National Today

Apr 14, 2026

Patients dosed with Cabaletta’s rese-cel manufactured on Cellares’ Cell Shuttle - TipRanks

Apr 14, 2026

Cabaletta Bio's Rese-cel Made on Cellares' Platform Given to First Patients - marketscreener.com

Apr 14, 2026

First patients dosed with Cabaletta Bio's rese-cel manufactured on Cellares' automated cell shuttle(TM) platform - marketscreener.com

Apr 14, 2026

First Patients Dosed With Cabaletta Bio’S Rese-Cel Manufactured On Cellares' Automated Cell Shuttle™ Platform - TradingView

Apr 14, 2026

Cellares and Cabaletta Bio Successfully Infuse First Patients with Rese-cel - Intellectia AI

Apr 14, 2026

Apr 13, 2026

Aug Retail: What is Cabaletta Bio Incs P E ratio telling usLayoff News & Fast Exit and Entry Trade Guides - baoquankhu1.vn

Apr 13, 2026

Cabaletta Bio, Inc. (NASDAQ:CABA) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat

Apr 13, 2026

Aug Wrap: Is Cabaletta Bio Inc stock trending bullishWeekly Stock Recap & Momentum Based Trading Ideas - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Cabaletta Bio (CABA) upgraded to buy: Here's what you should know - MSN

Apr 12, 2026

Apr 11, 2026

Institution Moves: Whats the MACD signal for Cabaletta Bio IncLong Setup & Weekly Watchlist for Hot Stocks - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026